Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Article in English | IMSEAR | ID: sea-135702

ABSTRACT

'Club drugs’ which include Ecstasy, gamma-hydroxybutyrate (GHB), ketamine, and Rohypnol (flunitrazepam) have become popular with participants in ‘raves’, because they are perceived to enhance energy, endurance, sociability and sexual arousal. These drugs vary in their pharmacologic properties, physiological and psychological effects, and potential consequences. The use of club drugs by young people has increased in the last decade, and continue to get modified and evolve, making them very difficult to monitor. Further, these drugs are not picked up by routine drugs screening procedures, thereby making these popular with the criminals. India, which is in a phase of social transition, also faces this rising menace. Despite the nature and extent of this problem, this area has been under-researched. Data from India are sparse barring a few newspaper and police reports. Keeping abreast of current trends in club drug use prepares the clinician to recognize the clinical effects of club drug use, to manage club drug related emergencies, and to generate social awareness.


Subject(s)
Anesthetics, Dissociative/adverse effects , Anti-Anxiety Agents/adverse effects , Designer Drugs/adverse effects , Flunitrazepam/adverse effects , Hallucinogens/adverse effects , Humans , India , Ketamine/adverse effects , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects , Psychotropic Drugs/adverse effects , Social Behavior , Illicit Drugs/adverse effects , Substance-Related Disorders
2.
Rev. Asoc. Med. Bahía Blanca ; 17(2): 34-39, abr.-jun. 2007.
Article in Spanish | LILACS, BINACIS | ID: lil-490161

ABSTRACT

El presente trabajo debe encuadrarse en la especialidad de la Medicina Legal. Sin embargo, no deja de implicar un aporte en el aspecto cotidiano asistencial ya que la obtención de psicofármacos requiere, muchas veces, la involuntaria participación del médico en calidad de agente prescriptor de tales drogas. El (mal) uso de las benzodiazepinas por parte de algunos sujetos, concepto distinto al de abuso, es una situación frecuente en el ámbito carcelario. Esta genera especiales y gravísimos conflictos que pueden, y deben, ser minimizados por la simple restricción de la prescripción farmacológica si esta se ajusta a la evidencia científica (prescripción basada en la evidencia) y no a las demandas, muchas veces (in)justificadas de los mismos pacientes-reclusos. La búsqueda y obtención -por parte de ciertos sujetos portadores de una personalidad predisponente- de los efectos paradojales de las benzodiazepinas, particularmente flunitrazepam y clonazepam, constituye un dato de la realidad que no puede ser desconocido ni minimizado por el médico asistencial ni por el experto en Medicina Legal, precisamente por las implicancias éticas, morales, sociales y, sobre todo, jurídicas que este supone, ni debe ser desoída la palabra profesional por los máximos responsables de la institución penitenciaria toda vez que a ellos compete el desarrollo e implementación de políticas tendientes a la cierta (re) socialización y (re) educación de la persona presa. Los destinatarios de este trabajo resultan entonces los médicos en general, con mayor énfasis en quienes trabajan en el medio penitenciario, pero también las autoridades del Servicio Penitenciario en todos sus escalafones y los integrantes del Poder Judicial...


Subject(s)
Humans , Benzodiazepines , Benzodiazepines/adverse effects , Benzodiazepines , Benzodiazepines/therapeutic use , Flunitrazepam/administration & dosage , Flunitrazepam , Flunitrazepam/adverse effects , Flunitrazepam/therapeutic use , Forensic Medicine/legislation & jurisprudence , Forensic Medicine/ethics
3.
Rev. bras. anestesiol ; 43(5): 297-302, set.-out. 1993. ilus, tab
Article in Portuguese | LILACS | ID: lil-159139

ABSTRACT

Flumazenil is a competitive inhibitor of the specific biding of benzodiazepines to central nervous system receptor sites and it is valuable in reversing their sedative effect. Twenty-four healthy patients (ASA I and II), both male and female, with age between 19 and 58 years and weight between 46 and 79 kg, scheduled for elective surgery under flunitrazepam oral premedication and intravenous sedation after spinal anesthesia, were submitted to a trial with flumazenil for reversal of sedation. Judged by the degree of sedaation, comprehension, cooperation and time and space orientation, flumazenil showed good results. Only 12 por cent of the patients presented resedation after 120 minutes. No adverse effect was observed.


Subject(s)
Humans , Adult , Anesthesia Recovery Period , Anesthesia, Epidural , Flumazenil/therapeutic use , Flunitrazepam/adverse effects , Flunitrazepam/antagonists & inhibitors
4.
Rev. Asoc. Méd. Argent ; 106(2): 4-8, 1993. ilus
Article in Spanish | LILACS | ID: lil-175471

ABSTRACT

Comunicamos el caso de un paciente de sexo masculino de 21 años de edad, enfermo de Sida por HIV que desarrolla mielomeningoencefalitis candidiásica asociada a meningitis por Tripanosoma cruzi. La enfermedad ocurrió en un paciente que vivía en un área de baja endemicidad para Tripanosomiasis Americana y sin antecedentes epidemiológicos compatibles con tal patología. El paciente es admitido en nuestro Servicio por presentar paresia braquial derecha, efectuándose punción lumbar que reveló parásitos flagelados móviles que correspondían a Tripanosoma cruzi. Dejamos abierto el interrogante acerca de la posibilidad que la transmisión pueda ocurrir a través de agujas compartidas por drogadictos intravenosos y el desarrollo de enfermedad en pacientes inmunodeficientes.


Subject(s)
Humans , Male , Adult , AIDS-Related Opportunistic Infections , Candidiasis/diagnosis , Chagas Disease/complications , Chagas Disease/diagnosis , Meningitis , Meningoencephalitis/diagnosis , Meningoencephalitis/mortality , Acquired Immunodeficiency Syndrome/complications , Central Nervous System/pathology , Cocaine/administration & dosage , Flunitrazepam/adverse effects , Paresis/diagnosis , Substance-Related Disorders
5.
J. bras. psiquiatr ; 40(4): 199-215, maio 1991. tab, graf
Article in Portuguese | LILACS | ID: lil-297998

ABSTRACT

Zopiclone é um hipnótico näo benzodiazepínico que, em ensaios preliminares, mostrou atividade hipnótica semelhante aos benzodiazepínicos, boa tolerância, ausência de efeitos sobre a memória, ausência de interaçäo com o álcool e baixo potencial de abuso. Este estudo trata-se de um ensaio duplo-cego, randomizado em grupos paralelos, entre Zopiclone e Flunitrazepam, em pacientes portadores de insônia crônica que visa comparar a eficácia dos dois hipnóticos, os efeitos residuais e os efeitos colaterais. Foram selecionados 50 pacientes ambulatoriais, que receberam 7,5 mg de Zopiclone ou 10 mg de Flunitrazepam, após uma semana de washout com placebo. Os pacientes foram avaliados a cada semana, durante quatro semanas, através do questionário do sono (Spiegel), da Auto-Avaliaçäo do Sono, do Teste de Substituiçäo de Dígitos e do Teste de Cópia de Símbolos. Foram registrados os efeitos colaterais relatados espontaneamente e utilizou-se a Escala TESS. Zopiclone mostro-se, efetivo na melhora de vários parâmetros da insônia e, algumas vezes, superior ao Flunitrazepam. Os efeitos colaterais principais de Zopiclone foram gosto amargo e boca seca


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Anti-Anxiety Agents , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/pharmacology , Sleep Initiation and Maintenance Disorders/drug therapy , Double-Blind Method , Drug Combinations , Flunitrazepam/adverse effects , Flunitrazepam/pharmacology , Sleep/drug effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL